Trials / Withdrawn
WithdrawnNCT01355562
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Loma Linda University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The current study will test single agent IL-2 in stage IV melanoma and kidney cancer.
Detailed description
The current study will test single agent IL-2 given daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting in stage IV melanoma and kidney cancer to attempt to determine the response rate, how long the responses last, and median survival of this regimen in these two diseases. Responding patients and those with absence of disease progression may receive additional cycles of therapy every 3 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interleukin-2 (IL-2) | Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2011-05-18
- Last updated
- 2020-04-30
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01355562. Inclusion in this directory is not an endorsement.